Although sales in Europe and North America are slowing, Reckitt Benckiser executives insist that sales will rise at the upper end of its target this year after reporting second-quarter revenue that topped analysts’ estimates. For the second quarter, sales rose 7% to $3.8 billion at current exchange rates. For the six months, sales rose 7% to more than $7.6 billion.
Non-pharmaceutical revenue will advance at the upper end of the 5-6% guidance the company had previously disclosed, the Slough, England-based company said today in a statement. Revenue on that basis, which excludes the impact of currency fluctuations, rose 6% in the period, faster than the 5.2% anticipated by analysts.
Reckitt Benckiser is looking to emerging markets such as Russia, the Middle East and Africa to compensate for slowing growth in Europe and North America, which make up about half of total revenue. The company is also grappling with declining sales at its pharmaceuticals business, which accounted for one-fifth of earnings last year.